Pharmacological Mechanisms of Low-intensity Focused Ultrasound for Motor Cortex Neuroplasticity (LIFUS-Pharma)

  • STATUS
    Recruiting
  • End date
    May 8, 2026
  • participants needed
    20
  • sponsor
    University Health Network, Toronto
Updated on 8 June 2022
Accepts healthy volunteers

Summary

Low-intensity focused ultrasound (LIFUS) has been shown to be an effective and safe non-invasive brain stimulation technique, capable of reaching greater brain depth and a greater spatial resolution than other brain stimulation tools. Its use as a potential clinical tool for treatment of neurological disorders is reliant on an understanding of its mechanisms of action. Although it has been shown to induce immediate (online) and prolonged (offline) changes in plasticity in the motor cortex, researchers have not studied its effects on neurotransmitter receptors and ion channels responsible for neuronal signaling in humans. The purpose of this study is to explore the effects of online and offline LIFUS stimulation in tandem with administration of various brain-active drugs, to elucidate the effects of this technique on specific cortical receptors and channels. 20 healthy, screened subjects will be recruited to participate in 5 sessions in-lab. Each session will represent the double-blinded administration of four known and studied pharmacological agents known to safely induce changes in the motor cortex, as well as a placebo. Investigators will use carbamazepine (sodium channel blocker), lorazepam (GABAA positive allosteric modulator), nimodipine (calcium channel blocker), and dextromethorphan (glutamate N-Methyl-D-aspartate receptor antagonist). Single- and paired-pulse transcranial magnetic stimulation (TMS) measures will be recorded for online LIFUS before and after drug intervention, and induction of offline LIFUS during placebo will be compared with its induction following the various drug interventions. Investigators predict that due to the differential effects of online and offline LIFUS on motor parameters, the mechanisms in which it alters the receptors and channels of interest will also be differentially modulated.

Description

In the current study investigators aim to describe how common neurotransmitter receptors and ion channels in the brain, particularly the motor cortex, are dynamically involved in the mechanisms generated by LIFUS. By selectively modulating the activity of these receptors and channels with previously studied and known drugs, it can be empirically determined how common components of signal propagation and prolonged neuroplasticity are being affected by the sonication waves induced by LIFUS. This will be done through baseline recording of FUS-induced neuroplasticity, and then compared within-subject to FUS-induced neuroplasticity after administration of pharmacological agents of interest. Random double-blinded administration of four drugs and a placebo will ensure that results are accurate and reduce any effects of expectation. Its predicted that online FUS will lead to a reduction in motor excitation and an increase in intracortical inhibition, and offline FUS will lead to an increase in motor excitation, an increase in intracortical facilitation, and a reduction in intracortical inhibition. Its predicted that drugs of interest to similarly replicate previous work; that is, carbamazepine, lorazepam, dextromethorphan, and nimodipine will all reduce cortical excitation and increase intracortical inhibition compared to placebo. Its predicted that carbamazepine, lorazepam, nimodipine and dextromethorphan will all further reduce motor excitation in conjunction with online FUS in an additive manner, compared to placebo. Its predicted that carbamazepine will have no effect on the prolonged effects of offline FUS on the motor cortex, but that lorazepam, nimodipine, and dextromethorphan will all interfere with the offline effects of FUS on motor cortex, compared to placebo.

Details
Condition Low Intensity Focussed Ultrasound
Treatment Placebo, dextromethorphan, Carbamazepine, Lorazepam, Nimodipine
Clinical Study IdentifierNCT04923659
SponsorUniversity Health Network, Toronto
Last Modified on8 June 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Right-handed healthy subjects between the ages of 18-65 will be included for recruitment

Exclusion Criteria

Diagnosed with any gait or postural disorders
Major neurological disease or disorder
Major musculoskeletal or nerve disorder, or disorder of hands, wrists and upper limbs
History of stroke or seizure
Diagnosed with dementia
Diagnosed with myasthenia gravis or acute narrow angle glaucoma
Has intracranial implant(s) or device(s)
Has an implanted cardiac pacemaker or implantable cardioverter-defibrillator (ICD)
Presence of metal implanted in body that is contraindicated in TMS
Caffeine or chocolate consumption 1-2 hours before study sessions
Consumption of grapefruit juice 24 hours before study sessions
Alcohol consumption 24 hours before study sessions
Pregnancy
Major depression/psychiatric disorder that in the opinion of the Investigator will affect patient's understanding of study procedures and willingness to abide by all procedures during the course of the study
Regular usage of CNS active drugs or calcium channel blockers during or up to 2 weeks before participating in the study
Is on antipsychotics, marijuana, or other recreational drugs (including tobacco) that affect the nervous system
Major cardiac, hematopoietic, liver, or kidney disease or infection
Treated hypertension
Hypersensitivity to benzodiazepines
Hypersensitivity to calcium channel blockers
Hypersensitivity to antitussives
Hypersensitivity to anticonvulsants
Regular usage of androgens, antibiotics, antifungals, antivirals, cardiovascular/gastrointestinal drugs, muscle relaxants, and platelet aggregation inhibitors during or up to 2 weeks before participating in the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note